Sputnik V rejected by Brazil’s health regulator: Russia says 61 countries have approve its COVID-19 vaccine


On Monday, Anvisa, which is the health regulator in Brazil, rejected a request by state governments to import Sputnik V, the COVID-19 vaccine made in Russia. All five board members voted against its approval saying it has “inherent risks” and “serious defects.” The Russian Direct Investment Fund (RDIF) who markets the vaccine said that this may be a politically motivated decision as 61 countries have approved its use and it has a high efficacy rate.


The general manager for health monitoring, Ana Carolina Moreira Marino Araujo said that they had reviewed the documentation presented as well as checked in-person data and obtained information from other regulators. They concluded that the “inherent risks” in Sputnik V were too great to be used in Brazil.



Brazil’s vaccination program has been beset with delays. The country is a hotspot for COVID-19. The health system is unable to cope with the daily rising numbers. A judicial enquiry on the lapses to procure oxygen is also underway.


According to data from the health ministry about 13 percent of the population which amounts to 27.3 million people has received a first dose of a COVId-19 vaccine. The country registered 14.4 million confirmed COVID-19 infections. The total death toll has also been one of the highest in the world and is reported to be almost 400,000.


Sputnik V is an adenovirus vaccine similar to vaccines produced by AstraZeneca and Johnson and Johnson. Clinical trials put its efficacy at almost 92 percent. A statement released by Moscow’s Gamaleya Institute where the vaccine was developed and the Russian Direct Investment Fund said that the real-world assessment produced better results. Data procured from 3.8 million who have taken the vaccine showed that Sputnik V was 97.6 percent effective.


European Medicines Agency, which is the European Union’s regulator, is reviewing Sputnik V. It is expected to decide whether it will use this vaccine by May or June.


Follow us on Google news for more updates and News


This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer